de Macedo Andrade Ana Cláudia, Felix Fernanda Aragão, França Glória Maria, Ribeiro Isabella Lima Arrais, Barboza Carlos Augusto Galvão, de Castro Ricardo Dias, de Lisboa Lopes Costa Antônio
Federal University of Rio Grande of Norte, Natal-RN, Brazil.
Department of Dentistry-UFRN, Natal-RN, Brazil.
Eur J Clin Pharmacol. 2022 Jun;78(6):919-930. doi: 10.1007/s00228-022-03299-x. Epub 2022 Mar 8.
The aim of this study is to investigate the association between hydrochlorothiazide (HCTZ) use and the risk of cutaneous and lip squamous cell carcinoma development.
We performed a systematic review and meta-analysis of case-control studies. We searched the Cochrane Library, PubMed, Scopus, Web of Science and LILACS. This study was registered in PROSPERO under protocol CRD42019129710. The meta-analysis was performed using the software Stata (version 12.0).
A total of 2181 published studies referring to the theme were identified, from which six were included in this systematic review. Men were more frequently affected by cutaneous and lip squamous cell carcinoma than women, with a 1.42:1 ratio. The mean age for cutaneous and lip squamous cell carcinoma development was 73.7 years. This meta-analysis demonstrated a chance of developing cutaneous and lip squamous cell carcinoma in any region of the body in hydrochlorothiazide users of 1.76-fold higher than in non-users. In addition, a risk factor of 1.80 higher (CI 95% = 1.71-1.89) of cutaneous squamous cell carcinoma in the head and neck region was observed in HCTZ users. Moreover, in the analysis of the dose used, the chance of developing squamous cell carcinoma was 3.37-fold lower when the concentration of HCTZ used was less than 50,000 mg.
Our results confirm the association between the use of hydrochlorothiazide and the cutaneous and lip squamous cell carcinoma development.
本研究旨在调查使用氢氯噻嗪（HCTZ）与皮肤及唇部鳞状细胞癌发生风险之间的关联。
我们对病例对照研究进行了系统评价和荟萃分析。我们检索了考克兰图书馆、PubMed、Scopus、科学网和拉丁美洲及加勒比地区卫生科学数据库。本研究已在国际前瞻性系统评价注册库（PROSPERO）中按照方案CRD42019129710进行注册。使用Stata软件（版本12.0）进行荟萃分析。
共识别出2181项涉及该主题的已发表研究，其中六项纳入了本系统评价。皮肤及唇部鳞状细胞癌男性患者比女性患者更常见，比例为1.42:1。皮肤及唇部鳞状细胞癌发病的平均年龄为73.7岁。该荟萃分析表明，使用氢氯噻嗪的患者身体任何部位发生皮肤及唇部鳞状细胞癌的几率比未使用者高1.76倍。此外，观察到使用氢氯噻嗪的患者头颈部皮肤鳞状细胞癌的风险因素高1.80倍（95%置信区间=1.71-1.89）。此外，在对使用剂量的分析中，当使用的氢氯噻嗪浓度低于50000毫克时，发生鳞状细胞癌的几率降低3.37倍。
我们的结果证实了使用氢氯噻嗪与皮肤及唇部鳞状细胞癌发生之间的关联。
